Arvinas Inc
NASDAQ:ARVN
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
17.83
52.31
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Arvinas Inc
Arvinas Inc
Total Receivables
Arvinas Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Arvinas Inc
NASDAQ:ARVN
|
Total Receivables
$14.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Receivables
$16.2B
|
CAGR 3-Years
3%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Receivables
$14.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
23%
|
CAGR 10-Years
17%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Receivables
$15.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Receivables
$12.2B
|
CAGR 3-Years
12%
|
CAGR 5-Years
8%
|
CAGR 10-Years
6%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Receivables
$12.1B
|
CAGR 3-Years
20%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
Arvinas Inc
Glance View
In the intricate world of biotechnology, Arvinas Inc. emerges as a pioneer, carving out a niche in the realm of targeted protein degradation. Founded by Dr. Craig Crews, the company stands at the forefront of innovation with its PROTAC® (PROteolysis TArgeting Chimeras) technology. This therapeutic approach cleverly harnesses the cell’s natural protein disposal system to degrade disease-causing proteins that have long evaded traditional drug targeting methods. By linking a target protein to an E3 ubiquitin ligase, PROTAC® molecules mark the unwanted proteins for cellular degradation, a strategy that potentially opens up a multitude of targets previously considered "undruggable." This inventive approach not only holds promise for treating a wide spectrum of diseases, including cancer and neurodegenerative disorders, but also positions Arvinas as a leader in redefining therapeutic paradigms. Focusing its business model on partnerships and collaborations, Arvinas has strategically aligned itself with some of the pharmaceutical industry's heavyweights. Revenue streams are derived from these collaborations, which include potential milestone payments, option fees, and royalties linked to the successful commercialization of therapeutics developed through its proprietary PROTAC® technology. By leveraging strategic alliances, Arvinas not only amplifies its research capabilities but also diversifies financial risk. The company is thus uniquely positioned at the intersection of science and commerce, driving innovation while capitalizing on its cutting-edge platform. This dual focus on robust scientific exploration and strategic financial growth creates a compelling narrative for a biotech company aiming to revolutionize disease treatment.
See Also
What is Arvinas Inc's Total Receivables?
Total Receivables
14.8m
USD
Based on the financial report for Sep 30, 2024, Arvinas Inc's Total Receivables amounts to 14.8m USD.
What is Arvinas Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
23%
Over the last year, the Total Receivables growth was -28%. The average annual Total Receivables growth rates for Arvinas Inc have been 20% over the past three years , 23% over the past five years .
You don't have any saved screeners yet
